Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, today announced the U.S Food and Drug Administration (FDA) approval of the Cochlear™ Nucleus® Nexa™ System ...

LONE TREE, Colo., July 8, 2025 /PRNewswire/ -- Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, today announced the U.S Food and Drug Administration (FDA) approval of ...

The Nucleus Nexa System builds upon Cochlear's industry-leading portfolio of electrodes, which are designed to optimize the electrode-neural interface and protect cochlear health for a lifetime of ...

Cochlear Limited, the global leader in implantable hearing solutions, announced the US Food and Drug Administration (FDA) approval of the Cochlear Nucleus Nexa System – the world’s first and only, ...

Upgradeable Firmware: The Cochlear™ Nucleus® Nexa™ System features upgradeable firmware on the implant – an industry first, allowing recipients to access future innovation through firmware ...

Cochlear Ltd. heard good news from the U.S. FDA, as the agency approved its next-generation cochlear implant, the Nucleus Nexa System, the first smart cochlear implant system. Cochlear expects to ...

With reporting season fast approaching, Macquarie has revealed its 2 least preferred ASX healthcare stocks in its coverage ...

An update from Cochlear ( (AU:COH) ) is now available.

"And while the Cochlear Nucleus Nexa System introduces several enhancements, it is based on the existing Nucleus 8 platform, with improvements appearing incremental and more about refining the ...